# Jounce Therapeutics
 (stock symbol: JNCE) Logo in transparent PNG format

## Jounce Therapeutics
 Logo large

### Jounce Therapeutics
 Logo large Download PNG (44.84 KB)

![Jounce Therapeutics
 Logo large Download PNG (44.84 KB)](/img/orig/JNCE_BIG-33f1ef21.png)

## Jounce Therapeutics
 Logo icon format

### Jounce Therapeutics
 Logo icon format Download PNG (67.66 KB)

![Jounce Therapeutics
 Logo icon format Download PNG (67.66 KB)](/img/orig/JNCE-90218175.png)

## About Jounce Therapeutics


Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

1. Website domain: jouncetx.com
2. Employees: 137
3. Marketcap: $0.10 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
